Scutellarin ameliorates nonalcoholic fatty liver disease through the PPARγ/PGC-1α-Nrf2 pathway. 2018

Xiaoxue Zhang, and Renpeng Ji, and Huijun Sun, and Jinyong Peng, and Xiaodong Ma, and ChangYuan Wang, and Yufeng Fu, and Liuchi Bao, and Yue Jin
a College of Pharmacy , Dalian Medical University , Dalian , China.

Nonalcoholic fatty liver disease (NAFLD) is characterised by excessive accumulation of hepatic lipids and oxidative injury of hepatocytes. Scutellarin is a flavonoid glycoside having antioxidative stress activity. Our current study aims to investigate the molecular mechanism of scutellarin ameliorating NAFLD. Scutellarin treatment was applied to male C57BL/6 mice maintained on a high-fat diet (HFD) and HepG2 cells challenged with oleic acid. The antioxidation biochemical indicators and lipid levels in the liver and cells were detected by kits. Liver pathology was observed by light microscope, Oil Red O staining, and transmission electron microscope (TEM). In addition, quantitative real-time polymerase chain reactions (qRT-PCR) and western blot assays were employed to detect the mRNA and protein levels of various antioxidative-related genes in the presence or absence of peroxisome proliferator-activated receptor gamma (PPARγ); inhibitor GW9662. Our results showed that scutellarin could significantly reduce blood lipid levels and enhance antioxidative capacities in both the models. In addition, scutellarin treatment conspicuously activated PPARγ, peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α), nuclear factor erythroid-2-related factor (Nrf2), haem oxygenase-1 (HO-1), glutathione S-transferase (GST), and NAD(P)H quinone dehydrogenase one (NQO1), while it significantly inhibited nuclear factor kappa B (NF-κB), Kelch-like ECH-associated protein 1 (Keap1) at both the mRNA and protein levels. However, after interfered by GW9662, scutellarin effect was significantly decreased. The experimental data demonstrated that scutellarin showed strong hypolipidaemic, antioxidative, and liver protective activity which could be attributed to its regulating activity in the PPARγ/PGC-1α-Nrf2 signaling pathway.

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D005965 Glucuronates Derivatives of GLUCURONIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that include the 6-carboxy glucose structure. Glucosiduronates,Glucuronic Acids,Acids, Glucuronic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000071248 Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha A transcriptional co-activator for NUCLEAR RECEPTORS. It is characterized by an N-terminal LxxLL sequence, a region that interacts with PPAR GAMMA, and a C-terminal RNA RECOGNITION MOTIF. It increases expression of MITOCHONDRIAL UNCOUPLING PROTEIN to regulate genes involved in metabolic reprogramming in response to dietary restriction and the integration of CIRCADIAN RHYTHMS with ENERGY METABOLISM. PGC-1-alpha Protein,PPARGC-1-alpha Protein,PPARGC1a Protein,PGC 1 alpha Protein,PPARGC 1 alpha Protein,Peroxisome Proliferator Activated Receptor Gamma Coactivator 1 alpha
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000960 Hypolipidemic Agents Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS. Antihyperlipidemic,Antilipemic,Antilipemic Agents,Antilipemic Drug,Hypolipidemic Agent,Hypolipidemic Drug,Antihyperlipemics,Antihyperlipidemics,Antilipemic Drugs,Antilipemics,Hypolipidemic Drugs,Agent, Hypolipidemic,Agents, Antilipemic,Agents, Hypolipidemic,Drug, Antilipemic,Drug, Hypolipidemic,Drugs, Antilipemic,Drugs, Hypolipidemic
D000975 Antioxidants Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. Anti-Oxidant,Antioxidant,Antioxidant Activity,Endogenous Antioxidant,Endogenous Antioxidants,Anti-Oxidant Effect,Anti-Oxidant Effects,Anti-Oxidants,Antioxidant Effect,Antioxidant Effects,Activity, Antioxidant,Anti Oxidant,Anti Oxidant Effect,Anti Oxidant Effects,Anti Oxidants,Antioxidant, Endogenous,Antioxidants, Endogenous
D015398 Signal Transduction The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway. Cell Signaling,Receptor-Mediated Signal Transduction,Signal Pathways,Receptor Mediated Signal Transduction,Signal Transduction Pathways,Signal Transduction Systems,Pathway, Signal,Pathway, Signal Transduction,Pathways, Signal,Pathways, Signal Transduction,Receptor-Mediated Signal Transductions,Signal Pathway,Signal Transduction Pathway,Signal Transduction System,Signal Transduction, Receptor-Mediated,Signal Transductions,Signal Transductions, Receptor-Mediated,System, Signal Transduction,Systems, Signal Transduction,Transduction, Signal,Transductions, Signal

Related Publications

Xiaoxue Zhang, and Renpeng Ji, and Huijun Sun, and Jinyong Peng, and Xiaodong Ma, and ChangYuan Wang, and Yufeng Fu, and Liuchi Bao, and Yue Jin
March 2016, Phytotherapy research : PTR,
Xiaoxue Zhang, and Renpeng Ji, and Huijun Sun, and Jinyong Peng, and Xiaodong Ma, and ChangYuan Wang, and Yufeng Fu, and Liuchi Bao, and Yue Jin
January 2020, BioMed research international,
Xiaoxue Zhang, and Renpeng Ji, and Huijun Sun, and Jinyong Peng, and Xiaodong Ma, and ChangYuan Wang, and Yufeng Fu, and Liuchi Bao, and Yue Jin
April 2023, Drug development research,
Xiaoxue Zhang, and Renpeng Ji, and Huijun Sun, and Jinyong Peng, and Xiaodong Ma, and ChangYuan Wang, and Yufeng Fu, and Liuchi Bao, and Yue Jin
January 2022, Brain research bulletin,
Xiaoxue Zhang, and Renpeng Ji, and Huijun Sun, and Jinyong Peng, and Xiaodong Ma, and ChangYuan Wang, and Yufeng Fu, and Liuchi Bao, and Yue Jin
November 2023, Biochemical and biophysical research communications,
Xiaoxue Zhang, and Renpeng Ji, and Huijun Sun, and Jinyong Peng, and Xiaodong Ma, and ChangYuan Wang, and Yufeng Fu, and Liuchi Bao, and Yue Jin
January 2022, Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica,
Xiaoxue Zhang, and Renpeng Ji, and Huijun Sun, and Jinyong Peng, and Xiaodong Ma, and ChangYuan Wang, and Yufeng Fu, and Liuchi Bao, and Yue Jin
May 2020, Biochemical and biophysical research communications,
Xiaoxue Zhang, and Renpeng Ji, and Huijun Sun, and Jinyong Peng, and Xiaodong Ma, and ChangYuan Wang, and Yufeng Fu, and Liuchi Bao, and Yue Jin
December 2019, World journal of gastroenterology,
Xiaoxue Zhang, and Renpeng Ji, and Huijun Sun, and Jinyong Peng, and Xiaodong Ma, and ChangYuan Wang, and Yufeng Fu, and Liuchi Bao, and Yue Jin
April 2023, Endocrine,
Xiaoxue Zhang, and Renpeng Ji, and Huijun Sun, and Jinyong Peng, and Xiaodong Ma, and ChangYuan Wang, and Yufeng Fu, and Liuchi Bao, and Yue Jin
November 2019, Digestive diseases and sciences,
Copied contents to your clipboard!